Stocks · News reference
Filed: 2026-09-08 AccNo: 0001193125-26-385194 Size: 257 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug
Intellia Therapeutics announced a $400 million non-dilutive senior secured term loan facility with OrbiMed, consisting of $75 million upfront and $325 million tied to milestones. The financing provides strategic flexibility as the company advances toward U.S. approval and commercial launch of lonvo-z for hereditary angioedema treatment, while also supporting advancement of nexiguran ziclumeran in transthyretin amyloidosis.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a